Literature DB >> 12221910

[Polymorphism in codon 72 of the p53 gene and cervico-uterine cancer risk in Mexico].

Angel Emillo Suárez-Rincón1, María Cristina Morán-Moguel, Héctor Montoya-Fuentes, Martha Patricia Gallegos-Arreola, José Sánchez-Corona.   

Abstract

A polymorphism at codon 72 in the p53 gen has been reported as a potential risk factor to cervical cancer (CC) because human papillomavirus (HPV) is more effective at degrading p53 Arg-72 than p53 Pro-72, making individuals homozygous for p53 Arg-72 seven times more likely to develop HPV-associated CC. As In Mexico the CC is a health public problem, we designed this study to determinate whether the p53 codon 72 polymorphism represent a risk factor to CC in our population. A case-controls study was performed. DNA was obtained from paraffin-embedded cervical fixed tissue samples. Analysis of the p53 genotype at position 72 was performed by polymerase chain reaction using specific primers and Accll digestion. Among cases with CC the proportions of the p53 genotypes at codon 72 were 0.05 to proline homozygous, 0.5 to heterozygous, and 0.45 to arginine-homozygous. In controls the proportions were 0.08, 0.62, and 0.31. X2 test showed no significant difference In the proportions. We conclude than In our population, as other worldwide countries, the homozygous for arginine at codon 72 of the p53 gene is not a risk factor to cervical cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12221910

Source DB:  PubMed          Journal:  Ginecol Obstet Mex        ISSN: 0300-9041


  1 in total

1.  Polymorphism in exon 4 of TP53 gene associated to HPV 16 and 18 in Mexican women with cervical cancer.

Authors:  Patricia Piña-Sánchez; Dulce María Hernández-Hernández; Lucia Taja-Chayeb; Ricardo M Cerda-Flores; Ana Lilia González-Herrera; Carlos Rodea-Avila; Teresa Apresa-García; Patricia Ostrosky-Wegman; Guelaguetza Vázquez-Ortíz; Patricia Mendoza-Lorenzo; Alfonso Dueñas-González; Mauricio Salcedo
Journal:  Med Oncol       Date:  2010-07-27       Impact factor: 3.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.